Challenges Implementing Remote Patient Monitoring for Hypertension
Tanjila Nawshin, Eric (Trombonist) Wallace, Tapan Mehta
us (code pays fourni par la source)
0 citations
JAMA Cardiology
Eric (Trombonist) Wallace
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
7Publications signalées
0Citations signalées
2Affiliations récentes
Les institutions déclarées
Les domaines associés
Trypanosoma species research and implicationsLysosomal Storage Disorders ResearchNon-Invasive Vital Sign MonitoringParasitic Diseases Research and TreatmentBlood Pressure and Hypertension Studies
Les publications récentes
Validation of a remote monitoring blood pressure device in a general population cohort
Matthew M Moore, Ayamo Oben, Paul Muntner, Stacy Harris et autres
BACKGROUND: Remote blood pressure (BP) monitoring has emerged as a promising solution to overcome barriers to hypertension care access, yet validation of devices is lacking. METHODS: We conducted the validation of the Ideal Life BP Manager BP device, a remote BP monitoring …
us (code pays fourni par la source)
0 citations
American Journal of Hypertension
Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study
Myrl D. Holida, Aleš Linhart, Nicola Longo, Eric (Trombonist) Wallace et autres
BACKGROUND: Enzyme replacement therapies (ERTs) approved for Fabry disease require infusions every 2 weeks (E2W). Pegunigalsidase alfa, a PEGylated ERT with a prolonged half-life vs. other ERTs, may allow extension of the dosing interval to every 4 weeks (E4W). BRIGHT F51 (NCT03614234) …
us, cz, pl, no, gb, be, dk, it, il (code pays fourni par la source)
0 citations
Orphanet Journal of Rare Diseases
Additional file 1 of Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study
Myrl Holida, Aleš Linhart, Nicola Longo, Eric (Trombonist) Wallace et autres
Supplementary Material 1
us, cz, no, gb, it, be, dk, il (code pays fourni par la source)
0 citations
Figshare
Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study
Myrl Holida, Aleš Linhart, Nicola Longo, Eric (Trombonist) Wallace et autres
Abstract Background Enzyme replacement therapies (ERTs) approved for Fabry disease require infusions every 2 weeks (E2W). Pegunigalsidase alfa, a PEGylated ERT with a prolonged half-life vs. other ERTs, may allow extension of the dosing interval to every 4 weeks (E4W). BRIGHT F51 …
us, cz, no, gb, it, be, dk, il (code pays fourni par la source)
0 citations
Figshare
Additional file 1 of Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study
Myrl Holida, Aleš Linhart, Nicola Longo, Eric (Trombonist) Wallace et autres
Supplementary Material 1
us, cz, no, gb, it, be, dk, il (code pays fourni par la source)
0 citations
Figshare
Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study
Myrl Holida, Aleš Linhart, Nicola Longo, Eric (Trombonist) Wallace et autres
Abstract Background Enzyme replacement therapies (ERTs) approved for Fabry disease require infusions every 2 weeks (E2W). Pegunigalsidase alfa, a PEGylated ERT with a prolonged half-life vs. other ERTs, may allow extension of the dosing interval to every 4 weeks (E4W). BRIGHT F51 …
us, cz, no, gb, it, be, dk, il (code pays fourni par la source)
0 citations
Figshare
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.